Exelixis Inc (EXEL) 2.82 $EXEL
Technical Briefing on Biotech Equities - Amgen, Exelixis, Sangamo BioSciences, Medivation, and Tekmira Pharma
PR Newswire - Fri Mar 20, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 135.56 (+1.09), SGMO: 17.63 (-0.91), TKMR: 19.48 (-1.01), AMGN: 170.10 (+0.99), EXEL: 2.82 (-0.02)
Is Exelixis (EXEL) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 7:45AM CDT
Exelixis is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
EXEL: 2.82 (-0.02)
Exelixis (EXEL) Highlighted As Weak On High Volume
at The Street - Thu Mar 12, 9:02AM CDT
Trade-Ideas LLC identified Exelixis (EXEL) as a weak on high relative volume candidate
EXEL: 2.82 (-0.02)
Why Exelixis, Inc. Shares Skyrocketed 57% in February
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 03, 7:54AM CST
What: Shares of cancer-focused biotechnology firm Exelixis skyrocketed by a whopping 57% in February, according to data from S&P Capital IQ , following the release of its fourth-quarter earnings results and updating the status of its new...
EXEL: 2.82 (-0.02)
Anaplastic Thyroid Cancer - Pipeline Review, H1 2015 - 9 Companies & 11 Drug Profiles
M2 - Mon Mar 02, 7:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/3kdpnn/anaplastic) has announced the addition of the "Anaplastic Thyroid Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Daiichi Sankyo Company, Limited - Exelixis, Inc. - Genelux Corporation - GlaxoSmithKline plc - Immune Pharmaceuticals, Ltd. - Novartis AG - OXiGENE, Inc. - Plexxikon Inc. - Takeda Oncology Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - cabozantinib s-malate - ceritinib - CLM-3 - CLM-94 - crolibulin - efatutazone - fosbretabulin tromethamine - GLONC-2 - MLN-0128 - PLX-8394 For more information visit http://www.researchandmarkets.com/research/3kdpnn/anaplastic
OXGN: 1.57 (-0.08), IMNP: 2.07 (-0.07), GSK: 48.81 (+0.60), NVS: 101.68 (+1.81), EXEL: 2.82 (-0.02)
First Week of EXEL April 17th Options Trading
StockOptionsChannel.com - Fri Feb 27, 9:45AM CST
Investors in Exelixis Inc saw new options begin trading this week, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EXEL options chain for the new April 17th contracts and identified one...
EXEL: 2.82 (-0.02)
Exelixis (EXEL) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 8:29AM CST
Exelixis (EXEL) Shares March Higher, Can It Continue?
EXEL: 2.82 (-0.02)
Looking Ahead at Exelixis, Inc.
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 25, 11:30AM CST
Exelixis sold $7.4 million worth of Cometriq and lost $58 million in the fourth quarter. With that out of the way, let's move on to more important matters. Because, let's face it, Exelixis could have sold half as much Cometriq or twice as much...
NVS: 101.68 (+1.81), EXEL: 2.82 (-0.02)
Exelixis' (EXEL) CEO Mike Morrissey on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 24, 8:17PM CST
EXEL: 2.82 (-0.02)
Exelixis reports 4Q loss
Automated Insights - Tue Feb 24, 6:12PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Exelixis Inc. (EXEL) on Tuesday reported a loss of $58 million in its fourth quarter.
EXEL: 2.82 (-0.02)
Exelixis (EXEL) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 24, 3:55PM CST
EXEL: 2.82 (-0.02)
Exelixis EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 3:19PM CST
EXEL: 2.82 (-0.02)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 4:35PM CST
AMRS: 2.34 (-0.16), AWAY: 31.29 (+0.33), HWAY: 21.46 (-0.09), FLTX: 44.22 (+0.70), HLS: 45.30 (+0.35), RRC: 49.35 (+1.70), DY: 46.96 (-0.13), MATX: 41.66 (+0.06), NYMT: 8.11 (+0.10), NSTG: 11.48 (-0.05), PZZA: 64.30 (+0.63), SGY: 14.10 (-0.01), HEP: 31.08 (-0.32), ARC: 8.80 (-0.09), BGFV: 13.54 (+0.44), RJET: 14.67 (+0.07), RLYP: 40.04 (unch), SAM: 277.36 (+9.46), DWA: 22.00 (+0.12), NKTR: 12.02 (+0.13), FSLR: 60.26 (-0.04), NFX: 33.29 (+0.82), KONA: 26.80 (+0.20), BBRG: 14.71 (+0.16), HEI: 59.84 (unch), CLR: 41.07 (+0.69), ACAS: 14.94 (+0.13), RUBI: 18.18 (-0.21), HURN: 66.50 (-0.88), GB: 56.06 (+0.57), BNFT: 39.22 (+0.92), AWK: 55.02 (+0.68), NUVA: 45.60 (-1.07), BOOM: 14.01 (unch), CENX: 14.04 (-0.11), GNMK: 13.82 (+0.36), QEP: 20.78 (+0.38), FMI: 48.11 (-0.29), KRA: 19.70 (+0.81), DPM: 38.79 (+1.03), JAZZ: 189.01 (+1.89), INFI: 15.39 (-1.14), EPR: 61.78 (+1.47), EXEL: 2.82 (-0.02), CBI: 45.29 (+0.86), NDSN: 78.26 (+0.13), ORA: 37.93 (+0.08), CPRT: 37.80 (+0.43), SM: 47.09 (+1.88), HPQ: 33.28 (+0.44), NLY: 10.74 (+0.04), LC: 20.09 (+0.17), DYN: 28.08 (+0.18), CLGX: 34.40 (+0.51), SLCA: 31.49 (+1.66), EIX: 64.17 (-0.64), MMSI: 19.40 (-0.02)
Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 1:30PM CST
Exelixis, Inc. (EXEL) is slated to report fourth-quarter 2014 results on Feb 24, 2015 and holds a Zacks Rank #3 (Hold) with an Earnings ESP of 0.00%.
IPXL: 46.34 (-0.47), SRPT: 13.16 (-0.76), EXEL: 2.82 (-0.02)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.10 (-0.04), AMRN: 2.52 (-0.03), HWAY: 21.46 (-0.09), HLS: 45.30 (+0.35), CYBX: 65.21 (-0.46), ESRX: 85.38 (+1.43), ECYT: 5.96 (-0.06), DXCM: 61.97 (-1.47), NSTG: 11.48 (-0.05), SRPT: 13.16 (-0.76), HZNP: 22.77 (-0.30), MDXG: 9.89 (-0.30), DEPO: 24.12 (-0.75), ANIK: 40.84 (-0.63), NKTR: 12.02 (+0.13), KERX: 14.31 (+0.68), ALIM: 5.12 (+0.08), EPZM: 19.91 (-0.88), AEGR: 27.20 (-0.20), MDRX: 12.05 (-0.06), ELGX: 16.49 (+0.07), NUVA: 45.60 (-1.07), HPTX: 40.49 (+0.85), GNMK: 13.82 (+0.36), MDVN: 135.56 (+1.09), HBIO: 5.40 (+0.13), ACAD: 34.45 (-0.54), ST: 57.45 (+0.54), RPTP: 11.86 (+0.14), FMI: 48.11 (-0.29), GMED: 24.61 (-0.53), JAZZ: 189.01 (+1.89), PTCT: 70.05 (+0.82), INFI: 15.39 (-1.14), ARNA: 4.80 (-0.21), EXEL: 2.82 (-0.02), NEO: 4.96 (+0.02), EXAS: 24.18 (-0.20), ALKS: 67.20 (-0.86), HTWR: 85.97 (-0.51), MNKD: 5.26 (-0.28), IPXL: 46.34 (-0.47), SQNM: 3.91 (-0.03), HALO: 14.63 (-1.43), ISIS: 73.59 (-3.49), CLVS: 78.26 (-3.17), BIO: 134.98 (-1.35), BIOS: 4.49 (-0.06), PCRX: 97.64 (-0.08)
Why Shares of Exelixis, Inc. Briefly Spiked Higher
George Budwell, The Motley Fool - Motley Fool - Thu Feb 19, 10:42AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of small-cap biopharma Exelixis spiked...
EXEL: 2.82 (-0.02)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 8:12AM CST
TTPH: 39.20 (-1.76), WLL: 39.03 (-1.04), EXXI: 3.83 (+0.07), NLST: 1.23 (-0.05), OIBR: 1.99 (+0.05), ASTI: 1.30 (-0.01), NVGN: 3.82 (-0.14), LIVE: 2.99 (+0.02), GTE: 2.54 (+0.03), PCLN: 1,179.17 (+2.85), GENE: 3.88 (-0.09), PWE: 1.51 (unch), GDP: 3.12 (+0.09), CLRX: 1.07 (-0.05), QTWW: 2.35 (+0.12), BJRI: 52.88 (-0.12), EOG: 90.68 (+1.15), VGGL: 1.64 (+0.19), OCRX: 4.95 (+0.10), CDE: 5.34 (+0.35), OAS: 13.80 (-0.16), EXEL: 2.82 (-0.02)
Ahead of the Bell: Exelixis shares climb, FDA to review drug
By The Associated Press - AP - Thu Feb 19, 8:03AM CST
Shares of Exelixis jumped in premarket trading Thursday after U.S. regulators said they would give a faster review to the drugmaker's potential treatment for a deadly form of skin cancer.
EXEL: 2.82 (-0.02)
Roche's melanoma combo NDA gets Priority Review
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 6:28AM CST
EXEL: 2.82 (-0.02)
Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Business Wire - Thu Feb 19, 12:00AM CST
Exelixis, Inc. (NASDAQ:EXEL) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Genentech's New Drug Application (NDA) for cobimetinib in combination with vemurafenib for patients with unresectable or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib is a specific MEK inhibitor that was discovered by Exelixis and is now the subject of a worldwide co-development agreement between Exelixis and Genentech, a member of the Roche Group.
EXEL: 2.82 (-0.02)
Technical Briefing on Biotech Equities - Amgen, Exelixis, Sangamo BioSciences, Medivation, and Tekmira Pharma
PR Newswire - Fri Mar 20, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 135.56 (+1.09), SGMO: 17.63 (-0.91), TKMR: 19.48 (-1.01), AMGN: 170.10 (+0.99), EXEL: 2.82 (-0.02)
Is Exelixis (EXEL) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 7:45AM CDT
Exelixis is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
EXEL: 2.82 (-0.02)
Exelixis (EXEL) Highlighted As Weak On High Volume
at The Street - Thu Mar 12, 9:02AM CDT
Trade-Ideas LLC identified Exelixis (EXEL) as a weak on high relative volume candidate
EXEL: 2.82 (-0.02)
Why Exelixis, Inc. Shares Skyrocketed 57% in February
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 03, 7:54AM CST
What: Shares of cancer-focused biotechnology firm Exelixis skyrocketed by a whopping 57% in February, according to data from S&P Capital IQ , following the release of its fourth-quarter earnings results and updating the status of its new...
EXEL: 2.82 (-0.02)
Anaplastic Thyroid Cancer - Pipeline Review, H1 2015 - 9 Companies & 11 Drug Profiles
M2 - Mon Mar 02, 7:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/3kdpnn/anaplastic) has announced the addition of the "Anaplastic Thyroid Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Daiichi Sankyo Company, Limited - Exelixis, Inc. - Genelux Corporation - GlaxoSmithKline plc - Immune Pharmaceuticals, Ltd. - Novartis AG - OXiGENE, Inc. - Plexxikon Inc. - Takeda Oncology Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - cabozantinib s-malate - ceritinib - CLM-3 - CLM-94 - crolibulin - efatutazone - fosbretabulin tromethamine - GLONC-2 - MLN-0128 - PLX-8394 For more information visit http://www.researchandmarkets.com/research/3kdpnn/anaplastic
OXGN: 1.57 (-0.08), IMNP: 2.07 (-0.07), GSK: 48.81 (+0.60), NVS: 101.68 (+1.81), EXEL: 2.82 (-0.02)
First Week of EXEL April 17th Options Trading
StockOptionsChannel.com - Fri Feb 27, 9:45AM CST
Investors in Exelixis Inc saw new options begin trading this week, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EXEL options chain for the new April 17th contracts and identified one...
EXEL: 2.82 (-0.02)
Exelixis (EXEL) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 8:29AM CST
Exelixis (EXEL) Shares March Higher, Can It Continue?
EXEL: 2.82 (-0.02)
Looking Ahead at Exelixis, Inc.
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 25, 11:30AM CST
Exelixis sold $7.4 million worth of Cometriq and lost $58 million in the fourth quarter. With that out of the way, let's move on to more important matters. Because, let's face it, Exelixis could have sold half as much Cometriq or twice as much...
NVS: 101.68 (+1.81), EXEL: 2.82 (-0.02)
Exelixis' (EXEL) CEO Mike Morrissey on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 24, 8:17PM CST
EXEL: 2.82 (-0.02)
Exelixis reports 4Q loss
Automated Insights - Tue Feb 24, 6:12PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Exelixis Inc. (EXEL) on Tuesday reported a loss of $58 million in its fourth quarter.
EXEL: 2.82 (-0.02)
Exelixis (EXEL) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 24, 3:55PM CST
EXEL: 2.82 (-0.02)
Exelixis EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 3:19PM CST
EXEL: 2.82 (-0.02)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 4:35PM CST
AMRS: 2.34 (-0.16), AWAY: 31.29 (+0.33), HWAY: 21.46 (-0.09), FLTX: 44.22 (+0.70), HLS: 45.30 (+0.35), RRC: 49.35 (+1.70), DY: 46.96 (-0.13), MATX: 41.66 (+0.06), NYMT: 8.11 (+0.10), NSTG: 11.48 (-0.05), PZZA: 64.30 (+0.63), SGY: 14.10 (-0.01), HEP: 31.08 (-0.32), ARC: 8.80 (-0.09), BGFV: 13.54 (+0.44), RJET: 14.67 (+0.07), RLYP: 40.04 (unch), SAM: 277.36 (+9.46), DWA: 22.00 (+0.12), NKTR: 12.02 (+0.13), FSLR: 60.26 (-0.04), NFX: 33.29 (+0.82), KONA: 26.80 (+0.20), BBRG: 14.71 (+0.16), HEI: 59.84 (unch), CLR: 41.07 (+0.69), ACAS: 14.94 (+0.13), RUBI: 18.18 (-0.21), HURN: 66.50 (-0.88), GB: 56.06 (+0.57), BNFT: 39.22 (+0.92), AWK: 55.02 (+0.68), NUVA: 45.60 (-1.07), BOOM: 14.01 (unch), CENX: 14.04 (-0.11), GNMK: 13.82 (+0.36), QEP: 20.78 (+0.38), FMI: 48.11 (-0.29), KRA: 19.70 (+0.81), DPM: 38.79 (+1.03), JAZZ: 189.01 (+1.89), INFI: 15.39 (-1.14), EPR: 61.78 (+1.47), EXEL: 2.82 (-0.02), CBI: 45.29 (+0.86), NDSN: 78.26 (+0.13), ORA: 37.93 (+0.08), CPRT: 37.80 (+0.43), SM: 47.09 (+1.88), HPQ: 33.28 (+0.44), NLY: 10.74 (+0.04), LC: 20.09 (+0.17), DYN: 28.08 (+0.18), CLGX: 34.40 (+0.51), SLCA: 31.49 (+1.66), EIX: 64.17 (-0.64), MMSI: 19.40 (-0.02)
Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 1:30PM CST
Exelixis, Inc. (EXEL) is slated to report fourth-quarter 2014 results on Feb 24, 2015 and holds a Zacks Rank #3 (Hold) with an Earnings ESP of 0.00%.
IPXL: 46.34 (-0.47), SRPT: 13.16 (-0.76), EXEL: 2.82 (-0.02)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.10 (-0.04), AMRN: 2.52 (-0.03), HWAY: 21.46 (-0.09), HLS: 45.30 (+0.35), CYBX: 65.21 (-0.46), ESRX: 85.38 (+1.43), ECYT: 5.96 (-0.06), DXCM: 61.97 (-1.47), NSTG: 11.48 (-0.05), SRPT: 13.16 (-0.76), HZNP: 22.77 (-0.30), MDXG: 9.89 (-0.30), DEPO: 24.12 (-0.75), ANIK: 40.84 (-0.63), NKTR: 12.02 (+0.13), KERX: 14.31 (+0.68), ALIM: 5.12 (+0.08), EPZM: 19.91 (-0.88), AEGR: 27.20 (-0.20), MDRX: 12.05 (-0.06), ELGX: 16.49 (+0.07), NUVA: 45.60 (-1.07), HPTX: 40.49 (+0.85), GNMK: 13.82 (+0.36), MDVN: 135.56 (+1.09), HBIO: 5.40 (+0.13), ACAD: 34.45 (-0.54), ST: 57.45 (+0.54), RPTP: 11.86 (+0.14), FMI: 48.11 (-0.29), GMED: 24.61 (-0.53), JAZZ: 189.01 (+1.89), PTCT: 70.05 (+0.82), INFI: 15.39 (-1.14), ARNA: 4.80 (-0.21), EXEL: 2.82 (-0.02), NEO: 4.96 (+0.02), EXAS: 24.18 (-0.20), ALKS: 67.20 (-0.86), HTWR: 85.97 (-0.51), MNKD: 5.26 (-0.28), IPXL: 46.34 (-0.47), SQNM: 3.91 (-0.03), HALO: 14.63 (-1.43), ISIS: 73.59 (-3.49), CLVS: 78.26 (-3.17), BIO: 134.98 (-1.35), BIOS: 4.49 (-0.06), PCRX: 97.64 (-0.08)
Why Shares of Exelixis, Inc. Briefly Spiked Higher
George Budwell, The Motley Fool - Motley Fool - Thu Feb 19, 10:42AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of small-cap biopharma Exelixis spiked...
EXEL: 2.82 (-0.02)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 8:12AM CST
TTPH: 39.20 (-1.76), WLL: 39.03 (-1.04), EXXI: 3.83 (+0.07), NLST: 1.23 (-0.05), OIBR: 1.99 (+0.05), ASTI: 1.30 (-0.01), NVGN: 3.82 (-0.14), LIVE: 2.99 (+0.02), GTE: 2.54 (+0.03), PCLN: 1,179.17 (+2.85), GENE: 3.88 (-0.09), PWE: 1.51 (unch), GDP: 3.12 (+0.09), CLRX: 1.07 (-0.05), QTWW: 2.35 (+0.12), BJRI: 52.88 (-0.12), EOG: 90.68 (+1.15), VGGL: 1.64 (+0.19), OCRX: 4.95 (+0.10), CDE: 5.34 (+0.35), OAS: 13.80 (-0.16), EXEL: 2.82 (-0.02)
Ahead of the Bell: Exelixis shares climb, FDA to review drug
By The Associated Press - AP - Thu Feb 19, 8:03AM CST
Shares of Exelixis jumped in premarket trading Thursday after U.S. regulators said they would give a faster review to the drugmaker's potential treatment for a deadly form of skin cancer.
EXEL: 2.82 (-0.02)
Roche's melanoma combo NDA gets Priority Review
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 6:28AM CST
EXEL: 2.82 (-0.02)
Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Business Wire - Thu Feb 19, 12:00AM CST
Exelixis, Inc. (NASDAQ:EXEL) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Genentech's New Drug Application (NDA) for cobimetinib in combination with vemurafenib for patients with unresectable or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib is a specific MEK inhibitor that was discovered by Exelixis and is now the subject of a worldwide co-development agreement between Exelixis and Genentech, a member of the Roche Group.
EXEL: 2.82 (-0.02)
